The MG-D-1509 consists of two small molecular compounds such as “Sorafenib” and the pure compound “MG005”, which can induce to new pass way and trigger to the new mechanism to treat solid tumor. The MG anti-cancer drug only attack the cancer tumor who has pDAPK positive expression, especially in multi-solid tumors can find. The study results have been published in a famous research journal “Cancer Research”.



　　First, MG anti-cancer drug facilitated pC-RafS338 and pDAPKS308 translocation from mitochondria to cytoplasm, leading to mitochondrial dysfunction and reactive oxygen species (ROS) generation. Second, ROS facilitated PP2A-mediated dephosphorylation of pDAPKS308 to DAPK. PP2A then dissociated from the C-Raf–DAPK complex and induced profound cancer cell death.



　　The novel anti-cancer drug can directly destroy cancer cells without inducing drug-resistance by changing the structures of target proteins and damaging mitochondria in cancer cells. The rationale of the drug is to “shut down the power plant of cancer cells and demolish cancer cells with heavy bombers”. Most importantly, the MG 1509 is indicated in up to 80% of cancers, and the anti-cancer effects are outstanding in lung cancers, colon cancers, breast cancers as well as melanoma.